Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
about
Novel therapeutic strategies for multiple myelomaMultifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.AKT as a therapeutic target in multiple myeloma.MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.Signaling Pathways and Emerging Therapies in Multiple Myeloma.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
P2860
Q28081590-7B6895B1-8010-46BA-AFEA-FDE71C8E97C5Q37460101-C5E70631-4922-4597-93F2-558B8735D3EAQ37697253-100162D9-91A4-49CB-8D5E-312125C066C3Q38112176-7B912174-2B85-4EFC-BC2C-5D9756AD333FQ38218256-66C479A2-3F39-4E15-A7A5-3EF4AA27A8A6Q38735514-7202D029-53BC-411A-8BCF-E19D2508A9B5Q38753307-657E4ED6-CC7C-41E4-A399-4D769B10D4B1Q38792725-5E54BA4A-F3D5-47E8-8BEA-3957BEDADD92Q38979939-72C45E2F-F3B2-4FCF-84E4-075591166770Q39277209-030ECA40-2983-47F3-9A06-70FD8A89ECEAQ41174750-527DDF7E-9277-4B60-901E-CF61E0D814B9Q47107700-891FC78F-E025-4911-92C7-8B790613325EQ53055574-31AC4DEC-AC18-4982-93E0-4E5A70D32ECB
P2860
Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Optimal induction of myeloma c ...... ined by translocation subtype.
@en
Optimal induction of myeloma c ...... ined by translocation subtype.
@nl
type
label
Optimal induction of myeloma c ...... ined by translocation subtype.
@en
Optimal induction of myeloma c ...... ined by translocation subtype.
@nl
prefLabel
Optimal induction of myeloma c ...... ined by translocation subtype.
@en
Optimal induction of myeloma c ...... ined by translocation subtype.
@nl
P2093
P2860
P356
P1433
P1476
Optimal induction of myeloma c ...... ined by translocation subtype.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2012.69
P577
2012-03-14T00:00:00Z
P5875
P6179
1013219026